{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["16(4)"],"submitter":["Elnaggar M"],"funding":["Novo Nordisk Ltd"],"pubmed_abstract":["Introduction
Glucagon-like peptide-1 (GLP-1) receptor agonists represent efficacious therapies for treating type 2 diabetes. Oral semaglutide is the only orally administered GLP-1 receptor agonist currently available and has been associated with reductions in glycated hemoglobin and body weight versus once-daily injectable liraglutide after 52 weeks in the PIONEER 4 clinical trial. As lower-cost liraglutide formulations have recently been developed, the present analysis evaluated the long-term cost-effectiveness of oral semaglutide 14 mg versus liraglutide 1.8 mg at lower acquisition costs in the UK.Methods
The published and validated PRIME Type 2 Diabetes Model was used to project clinical and cost outcomes over patient lifetimes. Baseline cohort characteristics, as well a"],"journal":["Diabetes therapy : research, treatment and education of diabetes and related disorders"],"pagination":["613-628"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11926313"],"repository":["biostudies-literature"],"pubmed_title":["The Long-Term Cost-Effectiveness of Oral Semaglutide Versus Lower-Cost Liraglutide in the UK."],"pmcid":["PMC11926313"],"pubmed_authors":["Mansinho JN","Hunt B","Whitaker J","Glah D","Ali S","Malkin SJP","Elnaggar M","MacLellan M"],"additional_accession":[]},"is_claimable":false,"name":"The Long-Term Cost-Effectiveness of Oral Semaglutide Versus Lower-Cost Liraglutide in the UK.","description":"Introduction
Glucagon-like peptide-1 (GLP-1) receptor agonists represent efficacious therapies for treating type 2 diabetes. Oral semaglutide is the only orally administered GLP-1 receptor agonist currently available and has been associated with reductions in glycated hemoglobin and body weight versus once-daily injectable liraglutide after 52 weeks in the PIONEER 4 clinical trial. As lower-cost liraglutide formulations have recently been developed, the present analysis evaluated the long-term cost-effectiveness of oral semaglutide 14 mg versus liraglutide 1.8 mg at lower acquisition costs in the UK.Methods
The published and validated PRIME Type 2 Diabetes Model was used to project clinical and cost outcomes over patient lifetimes. Baseline cohort characteristics, as well a","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Apr","modification":"2025-04-26T05:50:09.901Z","creation":"2025-04-06T11:38:28.87Z"},"accession":"S-EPMC11926313","cross_references":{"pubmed":["39969755"],"doi":["10.1007/s13300-025-01691-1"]}}